The Paradigm of Co-Development

In precision medicine, the therapeutic molecule and the diagnostic test are increasingly inseparable. Rather than developing a drug first and sourcing a diagnostic test post-approval, modern drug development relies on parallel drug-diagnostic co-development. By integrating companion diagnostics (CDx) early in clinical trial design, developers can identify the precise patient populations most likely to respond, significantly de-risking development timelines and improving success rates.

Historically, sequential development led to a critical bottleneck: the "diagnostic gap." When the therapeutic approval outpaces the diagnostic validation, the commercial launch is delayed, with historical data showing lags exceeding 700 days between drug and test approvals in certain indications. Synchronizing these developmental pathways from Phase I/II is the primary strategic challenge for developers of targeted therapies.

Navigating the Multi-Center Regulatory Pathway

Co-development requires navigating distinct regulatory bodies within the same agency. In the United States, drug validation is managed by the FDA’s Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER), while diagnostic assays (in vitro diagnostics, or IVDs) are evaluated by the Center for Devices and Radiological Health (CDRH).

This split authority introduces significant operational complexity:

• Investigational Device Exemptions (IDEs): Sponsors must determine early in trial design if the investigational CDx poses a "Significant Risk" to patients (e.g., if a false result leads to inappropriate treatment), requiring an IDE submission to CDRH before clinical trials can begin.

• Evolving Classifications: The FDA has proposed reclassifying certain oncology-based nucleic acid CDx from Class III (Premarket Approval, or PMA) to Class II (510(k)), potentially reducing review timelines. However, until this rule is finalized, sponsors must continue to plan for the more rigorous PMA pathway.

• Global IVDR Compliance: In Europe, the implementation of the In Vitro Diagnostic Regulation (IVDR) has increased the clinical evidence requirements for CDx, demanding rigorous safety and performance validation from independent notified bodies.

The Challenge of Cross-Industry Alliances

Because pharmaceutical companies rarely possess the capabilities to manufacture and distribute diagnostic hardware, co-development depends on cross-industry partnerships. Biopharma sponsors must form alliances with specialized diagnostic providers.

These partnerships frequently experience operational friction. Negotiating data rights—where pharma sponsors require broad access to patient genomic data for long-term discovery, while diagnostic partners seek to protect proprietary algorithms and comply with GDPR/HIPAA privacy regulations—is a major legal hurdle. Managing these partnerships requires dedicated alliance leaders who understand the business models and development cadences of both sectors.

Sourcing Leaders for the Drug-Diagnostic Interface

To execute successful co-development programmes, organisations must source Heads of Companion Diagnostics and CDx Alliance Directors who possess a unique hybrid profile. Leaders who only understand drug development or only understand medical devices cannot bridge the operational gap.

RSA prioritises several core competencies when placing CDx leaders:

• Dual-Pathway Regulatory Fluency: Deep familiarity with both drug submission pathways (IND/NDA/BLA) and device approval pathways (IDE/510(k)/PMA/IVDR), with a track record of managing joint pre-submission Q-submissions with CDER and CDRH.

• Pharma-Diagnostic Alliance Management: Experience negotiating complex commercial agreements, data-sharing protocols, and co-commercialisation strategies between biopharma and diagnostic companies.

• Biomarker and Assay Development Expertise: A strong scientific background in oncology, immunology, or genetics, with experience translating laboratory-developed assays into robust, clinical-grade diagnostic tests.

By securing leaders who can align these parallel development pipelines, life science companies can close the diagnostic gap, optimize clinical trial design, and deliver targeted therapies to patients with maximum commercial velocity.